Abstract 1672P
Background
Waiting involves staying in a place until an expected event occurs. From diagnosis to follow-up and treatment, cancer patients (pts) often endure waiting. Understanding their emotions during this time is crucial. Few studies have explored the experiences and emotions of cancer pts in the waiting room (WR).
Methods
An anonymous 12-item online questionnaire was distributed to cancer pts in our center's WR. The questionnaire was divided into 3 sections including clinical and socio-demographic information, time spent in the WR, and pts considerations. The aim of this study was to investigate cancer pts’ emotions and behaviors in the WR.
Results
160 pts completed the questionnaire (48% women, 52% men). The most common age groups were 51-65 years old (37%) and 66-80 years old (41%). The majority of pts are unemployed (58.5%). About half of interviewed pts undergo infusion therapies and/or visit 1-2 times monthly. When asked to describe the wait duration, approximately half found it long (32%) or too long (17%). Pts spend this period on mobile phones (47%), watching TV (21%), reading or listening to music (16%), and conversing with others (11%). Both positive (49% calm, 7.5% hopeful, 5% emotional involvement) and negative (26% boredom, 21% anxiety, 6% sadness, 5% anger, 1% apathy) emotions were experienced. The multiple logistic regression model confirms the independent predictor role for a negative emotional status in the WR of a perceived long or too long waiting period (OR=4.0, p<0.001) and the independent role of protector of male gender (OR=0.4, p0.008). A trend of significance emerged for employment (OR=0.4, p0.052) and engaging in active behaviors (OR=0.4, p0.058) as protective factors. When asked how to improve the quality of time in the WR, 38% suggested live entertainment (music, readings, and cancer information), 26% preferred access to newspapers and magazines. The most requested topics are treatment news (51%), diet (46%), and physical activity (27%).
Conclusions
For cancer pts the waiting can be a meaningful experience. Many pts find the wait long, boring, and anxiety-provoking. Our experience suggests how active and externalizing behaviors are less linked to negative emotions and interactive activities could improve the quality of time spent in the WR.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1687P - Perceptions of genetic testing and lived experiences in women with locally advanced or metastatic ovarian cancer: A focus on BRCAm and BRCAwt patients
Presenter: María Jesús Rubio Pérez
Session: Poster session 11
1688P - Psychosocial distress and spirituality among elderly patients with cancer in Nigeria
Presenter: Zainab Ogunjimi
Session: Poster session 11
1689TiP - The social stigma of smokers and patients with lung cancer: Detection of phoenomenon and testing of EMDR (eye movement desensitization and reprocessing) intervention
Presenter: Domenico Galetta
Session: Poster session 11
1692P - A phase Ib/IIa trial to evaluate the safety and efficacy of PM8002/ BNT327, a bispecific antibody targeting PD-L1 and VEGF-A, as a monotherapy in patients with advanced renal cell carcinoma
Presenter: Xinan Sheng
Session: Poster session 11
1693P - CaboPoint: Final results from a phase II study of cabozantinib after checkpoint inhibitor (CPI) combinations in patients with advanced renal cell carcinoma (aRCC)
Presenter: Laurence Albiges
Session: Poster session 11
1695P - Phase I LITESPARK-018: Dose escalation study of belzutifan in advanced pretreated clear cell renal cell carcinoma (ccRCC)
Presenter: Ulka Vaishampayan
Session: Poster session 11
1696P - A phase I/ II trial of pazopanib (Paz) alternating (alt) with bevacizumab (Bev) in treatment-naïve metastatic clear cell renal cell carcinoma (mccRCC) patients (pts): Phase II results
Presenter: Saby George
Session: Poster session 11
1697P - Phase II randomized double-blind trial of axitinib (Axi) +/- PF 04518600, an OX40 antibody (PFOX) after PD1/PDL1 antibody (IO) therapy (Tx) in metastatic renal cell carcinoma (mRCC): Final analysis
Presenter: Sarmad Sadeghi
Session: Poster session 11
1698P - Avelumab + axitinib (Ave + Axi) vs sunitinib (Sun) in advanced renal cell carcinoma (aRCC): Final analysis of patient (pt)-reported outcomes (PROs) and quality-adjusted time without symptoms or toxicity (Q-TWiST)
Presenter: Balaji Venugopal
Session: Poster session 11